Julia Hofmann

Ms. Julia Hofmann


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2026 in Cells
Verified
Journal Article
Open access
PDF file
ACAgata Izabela Ciosek
Agata Izabela Ciosek
JHJulia Hofmann
Julia Hofmann
KGKacper Galant
Kacper Galant
MMMatt Peter Marinkovich
Matt Peter Marinkovich
AWAgnieszka Wierzbowska
Agnieszka Wierzbowska
Aleksandra LesiakAleksandra Lesiak
Aleksandra Lesiak
Chimeric antigen receptor (CAR) T-cell therapy represents a major advance in modern immunotherapy. This narrative review summarizes evidence from the past five years, including case reports, case series, and clinical trials, on its application beyond hematologic malignancies, focusing on autoimmune diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), as well as solid tumors including melanoma and primary cutaneous lymphomas. CD19-directed CAR T-cells have demonstrated clinical benefits in SLE and SSc, with sustained immune reset, reduced autoreactive antibody levels, and clinical improvement. In melanoma, CAR T-cells targeting GD2, cMET, and CD20 have shown in vivo expansion and tumor infiltration; however, clinical efficacy remains limited, with transient stabilization or disease progression in most patients. In primary cutaneous lymphomas, early-phase studies with anti-CD70 and anti-CCR4.30 CAR T-cells indicate partial tumor regression and disease stabilization, often requiring additional therapy. Key challenges include limited durability of immune reset due to persistent plasma cells in autoimmune disorders, tumor heterogeneity, antigen loss or overlap, infiltration barriers, resistance mechanisms, and T-cell depletion in solid tumors, collectively reducing response durability and safety. The main toxicities include grade 1–2 cytokine release syndrome and rare hematologic complications, while immune effector cell-associated neurotoxicity syndrome is uncommon. Clinical translation remains limited and requires larger studies to improve efficacy and define safety profiles.

13 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ACAgata Izabela Ciosek
Agata Izabela Ciosek
JHJulia Hofmann
Julia Hofmann
KGKacper Galant
Kacper Galant
MMMatt Peter Marinkovich
Matt Peter Marinkovich
AWAgnieszka Wierzbowska
Agnieszka Wierzbowska
Aleksandra LesiakAleksandra Lesiak
Aleksandra Lesiak
Chimeric antigen receptor (CAR) T cell therapy represents one of the greatest breakthroughs in modern immunotherapies. To date, it has been approved by the Food and Drug Administration (FDA) for the treatment of several hematological malignancies, including different subtypes of leukemia, lymphoma, and multiple myeloma. However, recent reports suggest that CAR T therapy may also be effective in the treatment of severe systemic autoimmune diseases, such as systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). Case reports and small case series have demonstrated the efficacy of anti-CD19 CAR T cell therapy while maintaining a favorable safety profile. The most frequently reported adverse events include grade 1 or 2 cytokine release syndrome (CRS), hypogammaglobulinemia, and mild infectious complications. Moreover, CAR T therapy may also have potential in the treatment of advanced metastatic solid tumors, including melanoma. Early clinical studies have demonstrated the feasibility and safety of CAR T cell therapy in metastatic melanoma; however, several challenges remain. These include limited tumor trafficking and infiltration of CAR T cells, due to the presence of an immunosuppressive tumor microenvironment. Additionally, following the remarkable success of CAR T therapy in lymphomas, this approach may also be applied to the treatment of cutaneous lymphomas, including cutaneous T-cell and B-cell lymphomas. Key challenges include tumor heterogeneity, optimal target antigen selection, fratricidal activity of CAR T cells, and potential contamination of the CAR T product with lymphoma cells.

24 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JHJulia Hofmann
Julia Hofmann
ŁCŁukasz Chętko
Łukasz Chętko
IBIgor Bednarski
Igor Bednarski
MRMaria Rajczak
Maria Rajczak
MDMałgorzata Dominiak
Małgorzata Dominiak
Aleksandra LesiakAleksandra Lesiak
Aleksandra Lesiak
Background/Objectives: Alopecia areata (AA) is a widespread autoimmune condition causing non-scarring hair loss, significantly affecting the quality of life. Despite its prevalence, data on diagnostic and treatment efficacy and the quality of patients’ care in Poland remain unstudied. The aim of this study was to assess the current clinical approaches to the diagnosis and management of alopecia areata by dermatologists in Poland and to highlight the challenges encountered by Polish patients. Methods: A cross-sectional study was conducted regarding dermatologists and AA patients in Po-land. The data were gathered from distinct proprietary surveys: an original questionnaire for doctors, and DLQI, CDLQI, AAPPO, WPAI+CIQ:AS, and SF-36 questionnaires for patients. Results: The study included 100 dermatologists and 252 pa-tients from Poland. The study revealed that the care provided to patients with alopecia areata is inadequate and lacks a comprehensive approach, despite the negative disease impact on patients’ quality of life. A number of physicians do not follow the diagnostic and treatment guidelines. Despite the registration of next-generation treatments like Janus kinase inhibitors, access to these medications remained limited until recently. Conclusions: Alopecia areata in Poland poses significant diagnostic, therapeutic, and psychosocial challenges. While clinical practice largely aligns with international recommendations, notable gaps remain in the use of validated severity tools, psychosocial assessment, and access to advanced therapies. The recent reimbursement of ritlecitinib represents a breakthrough, bringing Polish care in line with global stand-ards. However, optimal management requires not only pharmacological advances but also interdisciplinary strategies integrating psychological support, patient advocacy, and public education to reduce stigma and improve overall quality of life for affected individuals.

1 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JHJulia Hofmann
Julia Hofmann
ŁCŁukasz Chętko
Łukasz Chętko
IBIgor Bednarski
Igor Bednarski
MRMaria Rajczak
Maria Rajczak
MDMałgorzata Dominiak
Małgorzata Dominiak
Aleksandra LesiakAleksandra Lesiak
Aleksandra Lesiak
Objectives: Alopecia areata (AA) is a widespread autoimmune condition causing non-scarring hair loss, significantly affecting the quality of life. Despite its prevalence, data on diagnostic and treatment efficacy and the quality of patient care in Poland remain unstudied. The aim of this study was to assess the current clinical approaches to the diagnosis and management of alopecia areata by dermatologists in Poland and to highlight the challenges encountered by Polish patients. Methods: A cross-sectional study was conducted regarding dermatologists and AA patients in Poland. The data were gathered from distinct proprietary surveys: an original questionnaire for doctors, and DLQI, CDLQI, AAPPO, WPAI+CIQ:AS, and SF-36 questionnaires for patients. Results: The study included 100 dermatologists and 252 patients from Poland. The study revealed that the care provided to patients with alopecia areata is inadequate and lacks a comprehensive approach, despite the negative disease impact on patients’ quality of life. A number of physicians do not follow the diagnostic and treatment guidelines. Despite the registration of next-generation treatments like Janus kinase inhibitors, access to these medications remained limited until recently. Conclusions: Alopecia areata in Poland poses significant diagnostic, therapeutic, and psychosocial challenges. While clinical practice largely aligns with international recommendations, notable gaps remain in the use of validated severity tools, psychosocial assessment, and access to advanced therapies. The recent reimbursement of ritlecitinib represents a breakthrough, bringing Polish care in line with global standards. However, optimal management requires not only pharmacological advances but also interdisciplinary strategies integrating psychological support, patient advocacy, and public education to reduce stigma and improve overall quality of life for affected individuals.

Verified
Journal Article
Open access
PDF file
ŁCŁukasz Chętko
Łukasz Chętko
JHJulia Hofmann
Julia Hofmann
KBKarolina Brzychcy
Karolina Brzychcy
MMMarta Matych
Marta Matych
DSDorota Sobolewska-Sztychny
Dorota Sobolewska-Sztychny
Aleksandra LesiakAleksandra Lesiak
Aleksandra Lesiak
Background: Alopecia areata (AA) is an autoimmune disease characterized by diverse patterns of non-scarring hair loss. Due to its susceptibility to immune dysregulation and psychological stress, there is growing speculation regarding the potential role of SARS-CoV-2 infection and the COVID-19 pandemic in its development, recurrence, or exacerbation. This retrospective study aimed to evaluate patients affected by AA from a single dermatological center, specifically focusing on the impact of the COVID-19 pandemic on hospitalization rates. Methods: Data comprising demographic characteristics, disease subtype, number, and duration of hospitalizations were digitized and statistically analyzed. The five-year period prior to the pandemic (2015–2019) was compared with the subsequent four years (2020–2023) to assess any changes. Results: The study involved 428 individuals (256 children and 172 adults), with a slight predominance of women (68.2%). The median ages in adults and children were 39.13 years and 8.66 years, respectively. Following the pandemic, there was a 13.81% decrease in the mean age among adult males. Hospitalizations surged by 207.62% after the pandemic, increasing from 223 to 686 admissions. Additionally, the diagnosis of alopecia areata totalis increased significantly by 55.6%. The residential distribution of pediatric patients also shifted notably, with 72.16% residing in urban areas and 27.84% in rural areas between 2020 and 2023. Conclusions: The significant increase in hospitalization rates and the diversity of disease subtypes observed in this study may suggest a potential correlation between COVID-19 and the development or altered course of alopecia areata. A deeper understanding of this association could enhance treatment outcomes in dermatology, ultimately improving patient care.